Ubs Group Ag Nautilus Biotechnology, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 27,781 shares of NAUT stock, worth $49,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,781

Previous 20,153 37.85%

Holding current value

$49,450

Previous $47,000 68.09%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.24 - $3.08 $17,086 - $23,494	7,628 Added 37.85%	27,781 $79,000
Q2 2024 Aug 13, 2024	SELL	$2.22 - $3.0 $69,783 - $94,302	-31,434 Reduced 60.93%	20,153 $47,000
Q1 2024 May 13, 2024	SELL	$2.41 - $3.18 $12,394 - $16,354	-5,143 Reduced 9.07%	51,587 $151,000
Q4 2023 Feb 09, 2024	BUY	$2.34 - $3.39 $67,857 - $98,306	28,999 Added 104.57%	56,730 $169,000
Q3 2023 Nov 09, 2023	SELL	$2.87 - $3.94 $8,130 - $11,162	-2,833 Reduced 9.27%	27,731 $87,000
Q2 2023 Aug 11, 2023	BUY	$2.21 - $4.52 $29,284 - $59,894	13,251 Added 76.54%	30,564 $118,000
Q1 2023 May 12, 2023	BUY	$1.67 - $2.77 $4,782 - $7,933	2,864 Added 19.82%	17,313 $47,000
Q4 2022 Feb 08, 2023	BUY	$1.55 - $2.47 $22,395 - $35,689	14,449 New	14,449 $26,000
Q2 2022 Aug 10, 2022	SELL	$2.64 - $4.84 $2,122 - $3,891	-804 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.5 - $5.3 $16,894 - $25,583	-4,827 Reduced 85.72%	804 $3,000
Q4 2021 Feb 14, 2022	SELL	$4.45 - $6.21 $140,984 - $196,745	-31,682 Reduced 84.91%	5,631 $30,000
Q3 2021 Nov 15, 2021	BUY	$6.14 - $10.1 $229,101 - $376,861	37,313 New	37,313 $229,000

Others Institutions Holding NAUT

# of Institutions

Shares Held

64.3M

Call Options Held

1.9K

Put Options Held

100

View Full List

About Nautilus Biotechnology, Inc.

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $222M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

More about NAUT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account